Loading news...
Veracyte (VCYT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Amalgamated Bank boosted its holdings in shares of Veracyte, Inc. (NASDAQ: VCYT) by 755.3% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,760 shares of the biotechnology company's stock after buying an additional 20,099 shares during the period. Amalgamated Bank's
Veracyte (VCYT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Oregon Public Employees Retirement Fund bought a new position in Veracyte, Inc. (NASDAQ: VCYT) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 17,700 shares of the biotechnology company's stock, valued at approximately $608,000. Other hedge funds and other
Veracyte (VCYT) has transitioned to a profitable, diversified model with strong operating leverage and self-fortifying balance sheet. Key 2025-2026 catalysts include deeper prostate cancer penetration, entry into minimal residual disease, and U.S. re-launch of the Prosigna breast cancer test. VCYT projects 16% revenue growth to $515–$517M in FY25 and >25% adjusted EBITDA margin, signaling sustained profitable execution.
Veracyte (NASDAQ: VCYT - Get Free Report) and Thermo Fisher Scientific (NYSE: TMO - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, earnings, dividends and risk. Profitability This table compares Veracyte and Thermo Fisher
Veracyte, Inc. (VCYT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. Preliminary Unaudited Financial Results For the fourth quarter ended December 31, 2025, as compared to the same period of 2024, Veracyte expects to report: Total revenue of between $138 million and $140 million, an increase of between 16% and 18% Testing revenue of.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 9:45 a.m. Pacific Time. Live audio webcasts of the company's presentations will be available by visiting Veracyte's website at http://investor.veracyte.com/events-presentations. A replay of the webcast will be available for 30 days following the conclu.
VCYT, IDXX and ISRG ride on genAI-powered growth as medical instruments evolve, even with weak industry returns and cost pressures.
Teleflex (NYSE: TFX - Get Free Report) and Veracyte (NASDAQ: VCYT - Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends. Profitability This table compares Teleflex and Veracyte's net margins,
Assenagon Asset Management S.A. decreased its position in Veracyte, Inc. (NASDAQ: VCYT) by 96.7% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 27,038 shares of the biotechnology company's stock after selling 803,061 shares during the period. Assenagon Asset Management
VCYT's Afirma and Decipher fuel strong test volume growth and a debt-free balance sheet, but rising macro costs and expenses temper the outlook.
Fisher Asset Management LLC lowered its position in Veracyte, Inc. (NASDAQ: VCYT) by 11.0% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 755,316 shares of the biotechnology company's stock after selling 93,297 shares during the quarter. Fisher Asset Management
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Nanovibronix (NASDAQ: NAOV - Get Free Report) and Veracyte (NASDAQ: VCYT - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability and analyst recommendations. Analyst Recommendations This is a breakdown of recent ratings and
Advantage Alpha Capital Partners LP lessened its position in shares of Veracyte, Inc. (NASDAQ: VCYT) by 27.2% in the second quarter, according to its most recent filing with the SEC. The firm owned 19,123 shares of the biotechnology company's stock after selling 7,161 shares during the quarter. Advantage Alpha Capital Partners LP's holdings
AXQ Capital LP bought a new position in shares of Veracyte, Inc. (NASDAQ: VCYT) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 9,080 shares of the biotechnology company's stock, valued at approximately $245,000. Other hedge funds and other institutional